| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Prostatic Neoplasms | 105 | 2023 | 1011 | 8.460 |
Why?
|
| Prostate | 33 | 2023 | 178 | 4.420 |
Why?
|
| Finasteride | 23 | 2020 | 37 | 2.370 |
Why?
|
| Prostate-Specific Antigen | 29 | 2023 | 162 | 1.390 |
Why?
|
| Urinary Bladder Neoplasms | 8 | 2024 | 226 | 1.190 |
Why?
|
| Biopsy | 28 | 2022 | 1081 | 1.160 |
Why?
|
| Adenocarcinoma | 9 | 2020 | 888 | 1.070 |
Why?
|
| Biopsy, Needle | 13 | 2016 | 188 | 1.040 |
Why?
|
| Prostatic Hyperplasia | 7 | 2015 | 42 | 1.030 |
Why?
|
| Neoplasm Grading | 14 | 2022 | 283 | 0.990 |
Why?
|
| Prostatitis | 7 | 2020 | 18 | 0.970 |
Why?
|
| Inflammation | 15 | 2021 | 2654 | 0.880 |
Why?
|
| Enzyme Inhibitors | 9 | 2008 | 809 | 0.810 |
Why?
|
| Male | 133 | 2023 | 62857 | 0.750 |
Why?
|
| 5-alpha Reductase Inhibitors | 10 | 2020 | 16 | 0.740 |
Why?
|
| Growth Differentiation Factor 15 | 4 | 2014 | 39 | 0.700 |
Why?
|
| Prostatectomy | 15 | 2022 | 106 | 0.680 |
Why?
|
| Immunotoxins | 3 | 2025 | 54 | 0.650 |
Why?
|
| Chemoprevention | 4 | 2009 | 90 | 0.650 |
Why?
|
| Calcitriol | 6 | 2016 | 53 | 0.650 |
Why?
|
| Anticarcinogenic Agents | 5 | 2015 | 77 | 0.640 |
Why?
|
| Receptors, Androgen | 4 | 2021 | 143 | 0.630 |
Why?
|
| Pelvic Pain | 5 | 2020 | 34 | 0.630 |
Why?
|
| Carcinoma | 4 | 2011 | 214 | 0.610 |
Why?
|
| Biomarkers, Tumor | 11 | 2021 | 1181 | 0.600 |
Why?
|
| Meningeal Neoplasms | 1 | 2019 | 93 | 0.580 |
Why?
|
| Serine Endopeptidases | 2 | 2019 | 117 | 0.580 |
Why?
|
| Humans | 150 | 2025 | 128417 | 0.570 |
Why?
|
| Middle Aged | 68 | 2023 | 30889 | 0.510 |
Why?
|
| Aged | 60 | 2023 | 21953 | 0.510 |
Why?
|
| Glomerulonephritis | 1 | 2015 | 46 | 0.490 |
Why?
|
| Proteinuria | 2 | 2014 | 88 | 0.470 |
Why?
|
| Selenium | 6 | 2022 | 36 | 0.470 |
Why?
|
| Antineoplastic Agents | 8 | 2024 | 2051 | 0.460 |
Why?
|
| Cystitis, Interstitial | 5 | 2017 | 15 | 0.460 |
Why?
|
| Trinucleotide Repeats | 1 | 2014 | 25 | 0.450 |
Why?
|
| Proto-Oncogene Proteins c-ets | 1 | 2014 | 53 | 0.440 |
Why?
|
| MAP Kinase Kinase Kinases | 3 | 2021 | 71 | 0.440 |
Why?
|
| Gene Expression Regulation, Neoplastic | 9 | 2021 | 1351 | 0.440 |
Why?
|
| Cell Line, Tumor | 15 | 2025 | 3184 | 0.410 |
Why?
|
| DNA Helicases | 3 | 2021 | 149 | 0.410 |
Why?
|
| Neoadjuvant Therapy | 4 | 2024 | 381 | 0.410 |
Why?
|
| Vitamin E | 6 | 2022 | 118 | 0.400 |
Why?
|
| Urothelium | 2 | 2014 | 37 | 0.400 |
Why?
|
| Imaging, Three-Dimensional | 5 | 2017 | 533 | 0.380 |
Why?
|
| Vitamin D | 4 | 2020 | 380 | 0.370 |
Why?
|
| Neoplasm Invasiveness | 9 | 2024 | 480 | 0.370 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 3 | 2008 | 371 | 0.360 |
Why?
|
| Dietary Supplements | 4 | 2011 | 531 | 0.360 |
Why?
|
| Neoplastic Cells, Circulating | 1 | 2011 | 70 | 0.360 |
Why?
|
| NF-kappa B | 1 | 2014 | 649 | 0.350 |
Why?
|
| Biomarkers | 11 | 2023 | 3880 | 0.350 |
Why?
|
| Bias | 4 | 2016 | 195 | 0.340 |
Why?
|
| Image-Guided Biopsy | 5 | 2017 | 37 | 0.330 |
Why?
|
| Brain Neoplasms | 1 | 2019 | 1163 | 0.330 |
Why?
|
| Immunohistochemistry | 17 | 2019 | 1664 | 0.330 |
Why?
|
| Chronic Pain | 3 | 2020 | 254 | 0.320 |
Why?
|
| Risk Assessment | 12 | 2020 | 3232 | 0.320 |
Why?
|
| Case-Control Studies | 13 | 2020 | 3328 | 0.310 |
Why?
|
| DNA-Binding Proteins | 4 | 2021 | 1421 | 0.310 |
Why?
|
| Neoplasm Recurrence, Local | 3 | 2023 | 958 | 0.310 |
Why?
|
| Proteins | 1 | 2014 | 932 | 0.310 |
Why?
|
| Testosterone | 4 | 2023 | 373 | 0.300 |
Why?
|
| Tumor Suppressor Protein p53 | 3 | 2008 | 508 | 0.300 |
Why?
|
| Neoplasm Proteins | 4 | 2016 | 421 | 0.280 |
Why?
|
| Polymorphism, Single Nucleotide | 7 | 2020 | 2062 | 0.280 |
Why?
|
| Neoplasm Staging | 11 | 2021 | 1290 | 0.280 |
Why?
|
| Cell Division | 4 | 2012 | 778 | 0.280 |
Why?
|
| Prognosis | 11 | 2021 | 3772 | 0.270 |
Why?
|
| Digital Rectal Examination | 5 | 2018 | 10 | 0.270 |
Why?
|
| Prostatic Diseases | 1 | 2006 | 5 | 0.270 |
Why?
|
| Aged, 80 and over | 19 | 2021 | 7033 | 0.270 |
Why?
|
| Carcinoma, Transitional Cell | 3 | 2014 | 60 | 0.270 |
Why?
|
| Incidence | 9 | 2016 | 2616 | 0.260 |
Why?
|
| Bone Morphogenetic Proteins | 1 | 2006 | 129 | 0.250 |
Why?
|
| Neoplasms, Experimental | 2 | 2017 | 169 | 0.250 |
Why?
|
| Androgens | 5 | 2021 | 173 | 0.250 |
Why?
|
| Unnecessary Procedures | 1 | 2005 | 48 | 0.240 |
Why?
|
| Prostatic Intraepithelial Neoplasia | 3 | 2013 | 12 | 0.240 |
Why?
|
| Protein Tyrosine Phosphatases | 2 | 2016 | 168 | 0.240 |
Why?
|
| CD47 Antigen | 1 | 2025 | 28 | 0.240 |
Why?
|
| Precursor T-Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2025 | 25 | 0.230 |
Why?
|
| Risk | 8 | 2020 | 853 | 0.230 |
Why?
|
| Diphtheria Toxin | 1 | 2025 | 64 | 0.230 |
Why?
|
| Models, Anatomic | 2 | 2004 | 92 | 0.230 |
Why?
|
| Interleukin-10 | 2 | 2017 | 299 | 0.230 |
Why?
|
| Genetic Predisposition to Disease | 6 | 2020 | 2264 | 0.230 |
Why?
|
| Atrophy | 4 | 2014 | 170 | 0.220 |
Why?
|
| Urinary Retention | 1 | 2023 | 21 | 0.220 |
Why?
|
| Neoplasm Metastasis | 7 | 2021 | 608 | 0.220 |
Why?
|
| Azotemia | 1 | 2023 | 7 | 0.210 |
Why?
|
| Triple Negative Breast Neoplasms | 2 | 2016 | 191 | 0.210 |
Why?
|
| Carcinoma in Situ | 1 | 2023 | 45 | 0.210 |
Why?
|
| Sezary Syndrome | 1 | 2023 | 44 | 0.210 |
Why?
|
| Hypogonadism | 1 | 2023 | 83 | 0.210 |
Why?
|
| Interleukin-2 | 3 | 2024 | 434 | 0.210 |
Why?
|
| Sensitivity and Specificity | 9 | 2017 | 1815 | 0.210 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 2 | 2020 | 413 | 0.210 |
Why?
|
| Mycosis Fungoides | 1 | 2023 | 63 | 0.210 |
Why?
|
| Severity of Illness Index | 5 | 2007 | 2721 | 0.210 |
Why?
|
| Lymphoma, T-Cell, Cutaneous | 1 | 2023 | 43 | 0.210 |
Why?
|
| Risk Factors | 14 | 2021 | 9704 | 0.200 |
Why?
|
| Hormone Replacement Therapy | 1 | 2023 | 89 | 0.200 |
Why?
|
| Phenotype | 6 | 2020 | 3044 | 0.200 |
Why?
|
| Disease Progression | 9 | 2016 | 2602 | 0.200 |
Why?
|
| Antigens, CD | 2 | 2015 | 482 | 0.190 |
Why?
|
| RNA Interference | 2 | 2021 | 441 | 0.190 |
Why?
|
| Observer Variation | 2 | 2013 | 312 | 0.190 |
Why?
|
| Antioxidants | 5 | 2015 | 538 | 0.180 |
Why?
|
| Acute Kidney Injury | 3 | 2023 | 773 | 0.180 |
Why?
|
| Animals | 28 | 2025 | 34479 | 0.180 |
Why?
|
| Clinical Trials as Topic | 5 | 2010 | 993 | 0.180 |
Why?
|
| ADAM10 Protein | 1 | 2021 | 30 | 0.180 |
Why?
|
| Randomized Controlled Trials as Topic | 7 | 2020 | 1356 | 0.180 |
Why?
|
| Retinoids | 1 | 2021 | 34 | 0.180 |
Why?
|
| Gamma Rays | 1 | 2021 | 52 | 0.180 |
Why?
|
| Signal Transduction | 10 | 2022 | 4826 | 0.170 |
Why?
|
| Amyloid Precursor Protein Secretases | 1 | 2021 | 81 | 0.170 |
Why?
|
| Mice | 19 | 2025 | 16602 | 0.170 |
Why?
|
| Equipment Design | 3 | 2017 | 518 | 0.170 |
Why?
|
| PTEN Phosphohydrolase | 2 | 2019 | 157 | 0.170 |
Why?
|
| Azasteroids | 2 | 2012 | 4 | 0.170 |
Why?
|
| Carotenoids | 2 | 2021 | 38 | 0.170 |
Why?
|
| Vitamin A | 2 | 2021 | 55 | 0.170 |
Why?
|
| Receptors, Calcitriol | 3 | 2010 | 53 | 0.170 |
Why?
|
| Radiation Injuries | 1 | 2021 | 135 | 0.160 |
Why?
|
| Placebos | 4 | 2020 | 201 | 0.160 |
Why?
|
| Needles | 2 | 2017 | 56 | 0.160 |
Why?
|
| Organ Size | 5 | 2019 | 440 | 0.160 |
Why?
|
| Fibrosis | 2 | 2021 | 512 | 0.160 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 3 | 2021 | 1559 | 0.160 |
Why?
|
| Survival Analysis | 5 | 2011 | 1263 | 0.160 |
Why?
|
| Follow-Up Studies | 11 | 2015 | 4892 | 0.160 |
Why?
|
| Parenchymal Tissue | 1 | 2019 | 6 | 0.160 |
Why?
|
| Gonadal Steroid Hormones | 1 | 2020 | 129 | 0.160 |
Why?
|
| Transcriptional Regulator ERG | 1 | 2019 | 17 | 0.160 |
Why?
|
| Epithelial-Mesenchymal Transition | 1 | 2021 | 199 | 0.160 |
Why?
|
| Focal Adhesions | 2 | 2016 | 44 | 0.160 |
Why?
|
| Reproducibility of Results | 5 | 2017 | 3020 | 0.150 |
Why?
|
| Treatment Outcome | 9 | 2023 | 10151 | 0.150 |
Why?
|
| Membrane Proteins | 2 | 2021 | 1105 | 0.150 |
Why?
|
| Transforming Growth Factor beta | 2 | 1998 | 445 | 0.150 |
Why?
|
| Image Interpretation, Computer-Assisted | 2 | 2018 | 254 | 0.150 |
Why?
|
| Rodentia | 1 | 1998 | 47 | 0.150 |
Why?
|
| Rats | 8 | 2024 | 5165 | 0.150 |
Why?
|
| Biomedical Research | 2 | 2014 | 635 | 0.150 |
Why?
|
| Symptom Flare Up | 1 | 2017 | 38 | 0.150 |
Why?
|
| Reagent Kits, Diagnostic | 1 | 2018 | 43 | 0.140 |
Why?
|
| Diagnostic Self Evaluation | 1 | 2017 | 22 | 0.140 |
Why?
|
| Carcinoma, Pancreatic Ductal | 1 | 2021 | 265 | 0.140 |
Why?
|
| Cell Cycle | 3 | 2021 | 581 | 0.140 |
Why?
|
| Odds Ratio | 4 | 2021 | 1023 | 0.140 |
Why?
|
| Neovascularization, Pathologic | 2 | 2013 | 290 | 0.140 |
Why?
|
| Predictive Value of Tests | 7 | 2012 | 1935 | 0.140 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2020 | 336 | 0.140 |
Why?
|
| Genetic Loci | 1 | 2018 | 274 | 0.140 |
Why?
|
| Neoplasms, Hormone-Dependent | 2 | 2003 | 38 | 0.140 |
Why?
|
| Bone Neoplasms | 1 | 2019 | 229 | 0.140 |
Why?
|
| Aspirin | 1 | 2020 | 376 | 0.140 |
Why?
|
| Biopsy, Large-Core Needle | 2 | 2016 | 13 | 0.140 |
Why?
|
| Kidney | 7 | 2005 | 1302 | 0.140 |
Why?
|
| Cell Movement | 3 | 2021 | 936 | 0.140 |
Why?
|
| Early Detection of Cancer | 4 | 2019 | 369 | 0.130 |
Why?
|
| Connective Tissue Growth Factor | 3 | 2013 | 24 | 0.130 |
Why?
|
| Ultrasonography, Interventional | 1 | 2017 | 128 | 0.130 |
Why?
|
| Androgen Antagonists | 2 | 2012 | 79 | 0.130 |
Why?
|
| DNA Damage | 3 | 2009 | 364 | 0.130 |
Why?
|
| Seminal Vesicles | 1 | 1995 | 9 | 0.130 |
Why?
|
| Sulfates | 1 | 2016 | 49 | 0.130 |
Why?
|
| Endosonography | 1 | 2017 | 142 | 0.130 |
Why?
|
| Interleukin-8 | 1 | 2017 | 258 | 0.130 |
Why?
|
| Blotting, Western | 6 | 2014 | 1164 | 0.130 |
Why?
|
| Actin Cytoskeleton | 1 | 2016 | 101 | 0.120 |
Why?
|
| Xenograft Model Antitumor Assays | 4 | 2025 | 814 | 0.120 |
Why?
|
| Tumor Microenvironment | 1 | 2019 | 623 | 0.120 |
Why?
|
| Skin Neoplasms | 1 | 2023 | 832 | 0.120 |
Why?
|
| Endoribonucleases | 1 | 2016 | 70 | 0.120 |
Why?
|
| United States | 11 | 2023 | 13830 | 0.120 |
Why?
|
| B7-1 Antigen | 2 | 2005 | 58 | 0.120 |
Why?
|
| Steroids | 1 | 2016 | 147 | 0.120 |
Why?
|
| Lower Urinary Tract Symptoms | 1 | 2016 | 54 | 0.120 |
Why?
|
| Glomerulosclerosis, Focal Segmental | 2 | 2005 | 42 | 0.120 |
Why?
|
| Telomere Shortening | 1 | 2015 | 19 | 0.120 |
Why?
|
| Urinary Tract | 1 | 2015 | 38 | 0.120 |
Why?
|
| Maryland | 1 | 2015 | 45 | 0.120 |
Why?
|
| CD8 Antigens | 1 | 2015 | 76 | 0.120 |
Why?
|
| Leukocyte Common Antigens | 1 | 2015 | 81 | 0.120 |
Why?
|
| Chemical Precipitation | 1 | 2014 | 37 | 0.120 |
Why?
|
| Antigens, Differentiation, Myelomonocytic | 1 | 2015 | 60 | 0.120 |
Why?
|
| Fatty Acids, Omega-6 | 1 | 2015 | 47 | 0.120 |
Why?
|
| Fibromuscular Dysplasia | 1 | 2014 | 7 | 0.120 |
Why?
|
| Cell Adhesion | 1 | 2016 | 445 | 0.120 |
Why?
|
| Tamoxifen | 1 | 1995 | 200 | 0.120 |
Why?
|
| Stromal Cells | 1 | 2015 | 105 | 0.120 |
Why?
|
| Nitric Oxide Synthase | 3 | 2004 | 232 | 0.120 |
Why?
|
| CD4 Antigens | 1 | 2015 | 138 | 0.120 |
Why?
|
| Ehlers-Danlos Syndrome | 1 | 2014 | 16 | 0.120 |
Why?
|
| Histone Demethylases | 1 | 2014 | 31 | 0.110 |
Why?
|
| Female | 23 | 2025 | 68153 | 0.110 |
Why?
|
| Reference Standards | 1 | 2014 | 168 | 0.110 |
Why?
|
| Ubiquitin Thiolesterase | 1 | 2014 | 42 | 0.110 |
Why?
|
| Neurofibromatosis 1 | 1 | 2014 | 45 | 0.110 |
Why?
|
| Adaptive Immunity | 1 | 2015 | 157 | 0.110 |
Why?
|
| Cerebral Arteries | 1 | 2014 | 57 | 0.110 |
Why?
|
| Ultrasonography | 1 | 2018 | 710 | 0.110 |
Why?
|
| Retrospective Studies | 8 | 2024 | 14454 | 0.110 |
Why?
|
| Prospective Studies | 8 | 2022 | 7036 | 0.110 |
Why?
|
| Kidney Tubular Necrosis, Acute | 2 | 2005 | 25 | 0.110 |
Why?
|
| Computer Simulation | 5 | 2018 | 939 | 0.110 |
Why?
|
| ras Proteins | 1 | 2014 | 145 | 0.110 |
Why?
|
| Microscopy, Fluorescence | 3 | 2011 | 399 | 0.110 |
Why?
|
| Fatty Acids, Omega-3 | 1 | 2015 | 137 | 0.110 |
Why?
|
| Survival Rate | 5 | 2021 | 1869 | 0.110 |
Why?
|
| Optics and Photonics | 1 | 2014 | 40 | 0.110 |
Why?
|
| Research Design | 6 | 2014 | 1036 | 0.110 |
Why?
|
| Body Mass Index | 2 | 2019 | 2261 | 0.110 |
Why?
|
| Mice, SCID | 2 | 2025 | 350 | 0.110 |
Why?
|
| Specimen Handling | 1 | 2014 | 164 | 0.110 |
Why?
|
| Cystic Duct | 1 | 1993 | 4 | 0.110 |
Why?
|
| B7-H1 Antigen | 1 | 2015 | 189 | 0.110 |
Why?
|
| Immediate-Early Proteins | 2 | 2005 | 51 | 0.110 |
Why?
|
| Cystectomy | 2 | 2024 | 38 | 0.110 |
Why?
|
| Disease Models, Animal | 5 | 2023 | 3937 | 0.110 |
Why?
|
| Veratrum Alkaloids | 1 | 2013 | 19 | 0.110 |
Why?
|
| Cholelithiasis | 1 | 1993 | 36 | 0.110 |
Why?
|
| Polyglycolic Acid | 1 | 1993 | 41 | 0.100 |
Why?
|
| Spectrometry, Fluorescence | 1 | 2014 | 170 | 0.100 |
Why?
|
| Mitogen-Activated Protein Kinases | 1 | 2014 | 312 | 0.100 |
Why?
|
| Pancreatic Neoplasms | 1 | 2021 | 875 | 0.100 |
Why?
|
| Somatomedins | 1 | 2013 | 28 | 0.100 |
Why?
|
| Insulin-Like Growth Factor Binding Proteins | 1 | 2013 | 29 | 0.100 |
Why?
|
| Random Allocation | 1 | 2013 | 343 | 0.100 |
Why?
|
| Deoxycytidine | 2 | 2024 | 163 | 0.100 |
Why?
|
| Double-Blind Method | 6 | 2020 | 1848 | 0.100 |
Why?
|
| Muscles | 2 | 2024 | 322 | 0.100 |
Why?
|
| Adult | 23 | 2020 | 35299 | 0.100 |
Why?
|
| Penile Neoplasms | 1 | 1992 | 7 | 0.100 |
Why?
|
| Health Status Disparities | 1 | 2015 | 254 | 0.100 |
Why?
|
| Penis | 1 | 1992 | 35 | 0.100 |
Why?
|
| Swine | 3 | 2024 | 742 | 0.100 |
Why?
|
| Telomerase | 1 | 2014 | 231 | 0.100 |
Why?
|
| Tumor Suppressor Proteins | 1 | 2014 | 313 | 0.100 |
Why?
|
| Sterol Regulatory Element Binding Protein 2 | 3 | 2005 | 8 | 0.090 |
Why?
|
| Hedgehog Proteins | 1 | 2013 | 187 | 0.090 |
Why?
|
| Cisplatin | 2 | 2024 | 297 | 0.090 |
Why?
|
| Mice, Inbred C57BL | 8 | 2023 | 5272 | 0.090 |
Why?
|
| Sterol Regulatory Element Binding Protein 1 | 3 | 2005 | 57 | 0.090 |
Why?
|
| Caspase 1 | 2 | 2002 | 142 | 0.090 |
Why?
|
| Frozen Sections | 1 | 2011 | 25 | 0.090 |
Why?
|
| Logistic Models | 3 | 2021 | 1974 | 0.090 |
Why?
|
| Practice Guidelines as Topic | 2 | 2016 | 1478 | 0.090 |
Why?
|
| Isoenzymes | 3 | 2004 | 304 | 0.090 |
Why?
|
| Metabolomics | 1 | 2016 | 599 | 0.090 |
Why?
|
| Alkylating Agents | 1 | 2010 | 24 | 0.090 |
Why?
|
| Gonadotropin-Releasing Hormone | 1 | 2012 | 207 | 0.090 |
Why?
|
| Cohort Studies | 5 | 2020 | 5388 | 0.090 |
Why?
|
| beta Carotene | 1 | 2010 | 21 | 0.090 |
Why?
|
| Interleukin-18 | 2 | 2002 | 236 | 0.090 |
Why?
|
| Antineoplastic Agents, Hormonal | 3 | 2013 | 158 | 0.090 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2016 | 758 | 0.090 |
Why?
|
| In Situ Hybridization, Fluorescence | 1 | 2011 | 313 | 0.090 |
Why?
|
| ROC Curve | 3 | 2008 | 500 | 0.090 |
Why?
|
| Myofibromatosis | 2 | 2001 | 10 | 0.080 |
Why?
|
| Apoptosis | 5 | 2021 | 2435 | 0.080 |
Why?
|
| Cell Separation | 1 | 2011 | 313 | 0.080 |
Why?
|
| Multivariate Analysis | 2 | 2011 | 1484 | 0.080 |
Why?
|
| Nuclear Proteins | 1 | 2014 | 657 | 0.080 |
Why?
|
| ErbB Receptors | 1 | 2013 | 601 | 0.080 |
Why?
|
| Mammary Glands, Human | 1 | 2010 | 64 | 0.080 |
Why?
|
| Immunity, Innate | 1 | 2015 | 802 | 0.080 |
Why?
|
| p300-CBP Transcription Factors | 1 | 2009 | 21 | 0.080 |
Why?
|
| Mammary Glands, Animal | 1 | 2010 | 124 | 0.080 |
Why?
|
| Chronic Disease | 4 | 2017 | 1705 | 0.080 |
Why?
|
| Time Factors | 7 | 2016 | 6482 | 0.080 |
Why?
|
| Macrophage Activation | 1 | 2010 | 187 | 0.080 |
Why?
|
| TGF-beta Superfamily Proteins | 1 | 2008 | 5 | 0.080 |
Why?
|
| Kidney Diseases | 2 | 2005 | 367 | 0.080 |
Why?
|
| RNA, Neoplasm | 2 | 2006 | 87 | 0.080 |
Why?
|
| Antibodies, Monoclonal | 4 | 2024 | 1355 | 0.080 |
Why?
|
| 3-Oxo-5-alpha-Steroid 4-Dehydrogenase | 1 | 2008 | 8 | 0.080 |
Why?
|
| Genetic Markers | 1 | 2009 | 338 | 0.080 |
Why?
|
| DNA Primers | 2 | 2006 | 510 | 0.080 |
Why?
|
| Autopsy | 4 | 2013 | 92 | 0.070 |
Why?
|
| Bacteria | 1 | 2015 | 808 | 0.070 |
Why?
|
| BK Virus | 1 | 2008 | 13 | 0.070 |
Why?
|
| Vitamins | 2 | 2022 | 174 | 0.070 |
Why?
|
| Nephritis | 1 | 2008 | 21 | 0.070 |
Why?
|
| Polyomavirus Infections | 1 | 2008 | 27 | 0.070 |
Why?
|
| Head and Neck Neoplasms | 1 | 2013 | 533 | 0.070 |
Why?
|
| Nitriles | 2 | 2021 | 157 | 0.070 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2013 | 620 | 0.070 |
Why?
|
| Obesity | 2 | 2015 | 2858 | 0.070 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2013 | 755 | 0.070 |
Why?
|
| Cell Hypoxia | 1 | 2008 | 229 | 0.070 |
Why?
|
| Puerto Rico | 2 | 2019 | 52 | 0.070 |
Why?
|
| Microbiota | 1 | 2015 | 719 | 0.070 |
Why?
|
| Gene Expression Profiling | 3 | 2019 | 1688 | 0.070 |
Why?
|
| Collagen | 1 | 2010 | 429 | 0.070 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 2 | 2006 | 756 | 0.070 |
Why?
|
| Lymphatic Metastasis | 1 | 2008 | 318 | 0.070 |
Why?
|
| Tumor Burden | 1 | 2008 | 283 | 0.070 |
Why?
|
| Fibroblast Growth Factors | 1 | 2008 | 170 | 0.070 |
Why?
|
| Magnetic Resonance Imaging | 2 | 2017 | 3376 | 0.070 |
Why?
|
| Drosophila melanogaster | 1 | 2009 | 217 | 0.070 |
Why?
|
| Mice, Nude | 3 | 2014 | 682 | 0.070 |
Why?
|
| Postpartum Period | 1 | 2010 | 330 | 0.070 |
Why?
|
| Rats, Nude | 1 | 2006 | 27 | 0.070 |
Why?
|
| Lysine | 1 | 2009 | 278 | 0.070 |
Why?
|
| Cell Proliferation | 3 | 2021 | 2344 | 0.070 |
Why?
|
| Canada | 2 | 2019 | 344 | 0.070 |
Why?
|
| Kidney Neoplasms | 1 | 2010 | 349 | 0.070 |
Why?
|
| Caspases | 2 | 2010 | 242 | 0.070 |
Why?
|
| Transplantation, Heterologous | 1 | 2006 | 187 | 0.060 |
Why?
|
| Scleroderma, Systemic | 1 | 2007 | 104 | 0.060 |
Why?
|
| Cholestenone 5 alpha-Reductase | 1 | 2005 | 3 | 0.060 |
Why?
|
| Calcium | 1 | 2012 | 1178 | 0.060 |
Why?
|
| Kallikreins | 2 | 2018 | 29 | 0.060 |
Why?
|
| Sterol Regulatory Element Binding Proteins | 1 | 2005 | 2 | 0.060 |
Why?
|
| Cell Line | 4 | 2014 | 2731 | 0.060 |
Why?
|
| CCAAT-Enhancer-Binding Proteins | 1 | 2005 | 37 | 0.060 |
Why?
|
| Antigens, Neoplasm | 2 | 2007 | 309 | 0.060 |
Why?
|
| Longitudinal Studies | 3 | 2020 | 2710 | 0.060 |
Why?
|
| Lipid Metabolism | 2 | 2005 | 491 | 0.060 |
Why?
|
| Animal Feed | 1 | 2005 | 50 | 0.060 |
Why?
|
| Drug Screening Assays, Antitumor | 2 | 2016 | 195 | 0.060 |
Why?
|
| Urinalysis | 2 | 2015 | 69 | 0.060 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 2 | 2005 | 940 | 0.060 |
Why?
|
| Protein Processing, Post-Translational | 2 | 2013 | 449 | 0.060 |
Why?
|
| Polymorphism, Genetic | 1 | 2008 | 639 | 0.060 |
Why?
|
| Tumor Cells, Cultured | 2 | 2021 | 930 | 0.060 |
Why?
|
| Cell Adhesion Molecules | 1 | 2006 | 172 | 0.060 |
Why?
|
| National Institute of Diabetes and Digestive and Kidney Diseases (U.S.) | 2 | 2014 | 9 | 0.060 |
Why?
|
| Vascular Endothelial Growth Factor A | 2 | 2005 | 500 | 0.060 |
Why?
|
| Kidney Failure, Chronic | 2 | 2008 | 535 | 0.060 |
Why?
|
| Carcinoma, Lobular | 1 | 2005 | 48 | 0.060 |
Why?
|
| Transcriptional Activation | 1 | 2006 | 356 | 0.060 |
Why?
|
| DNA Methylation | 1 | 2009 | 604 | 0.060 |
Why?
|
| Carcinoma, Ductal, Breast | 1 | 2005 | 82 | 0.060 |
Why?
|
| Receptors, CCR4 | 1 | 2024 | 21 | 0.060 |
Why?
|
| Weight Gain | 1 | 2008 | 503 | 0.060 |
Why?
|
| Models, Statistical | 1 | 2008 | 621 | 0.060 |
Why?
|
| Doxazosin | 1 | 2003 | 3 | 0.060 |
Why?
|
| Genotype | 3 | 2020 | 1828 | 0.060 |
Why?
|
| Reactive Nitrogen Species | 1 | 2004 | 22 | 0.060 |
Why?
|
| Image Processing, Computer-Assisted | 2 | 2005 | 735 | 0.060 |
Why?
|
| Prostaglandin-Endoperoxide Synthases | 1 | 2004 | 73 | 0.060 |
Why?
|
| Caloric Restriction | 1 | 2005 | 108 | 0.060 |
Why?
|
| Adrenergic alpha-Antagonists | 1 | 2003 | 32 | 0.060 |
Why?
|
| DNA Fingerprinting | 1 | 2003 | 25 | 0.050 |
Why?
|
| Biliary Atresia | 1 | 2005 | 160 | 0.050 |
Why?
|
| Complement Pathway, Alternative | 1 | 2005 | 113 | 0.050 |
Why?
|
| Swine, Miniature | 1 | 2024 | 79 | 0.050 |
Why?
|
| Karyotyping | 1 | 2003 | 107 | 0.050 |
Why?
|
| Germinoma | 1 | 2003 | 13 | 0.050 |
Why?
|
| Endotoxins | 1 | 2004 | 216 | 0.050 |
Why?
|
| Administration, Intravesical | 1 | 2023 | 15 | 0.050 |
Why?
|
| Body Weight | 3 | 2020 | 928 | 0.050 |
Why?
|
| Histones | 1 | 2009 | 586 | 0.050 |
Why?
|
| Acute-Phase Reaction | 1 | 2023 | 40 | 0.050 |
Why?
|
| Syndrome | 2 | 2014 | 335 | 0.050 |
Why?
|
| BCG Vaccine | 1 | 2023 | 24 | 0.050 |
Why?
|
| Causality | 1 | 2004 | 116 | 0.050 |
Why?
|
| Furosemide | 1 | 2023 | 38 | 0.050 |
Why?
|
| Liver Cirrhosis | 1 | 2005 | 275 | 0.050 |
Why?
|
| Clinical Trials, Phase III as Topic | 2 | 2016 | 90 | 0.050 |
Why?
|
| Mortality | 1 | 2005 | 307 | 0.050 |
Why?
|
| Interdisciplinary Communication | 2 | 2014 | 187 | 0.050 |
Why?
|
| Cyclooxygenase 2 | 1 | 2004 | 172 | 0.050 |
Why?
|
| DNA, Neoplasm | 1 | 2003 | 159 | 0.050 |
Why?
|
| Heart Neoplasms | 1 | 2003 | 49 | 0.050 |
Why?
|
| Lipocalin-2 | 1 | 2023 | 76 | 0.050 |
Why?
|
| Glomerular Filtration Rate | 2 | 2023 | 681 | 0.050 |
Why?
|
| Mice, Inbred NOD | 1 | 2025 | 586 | 0.050 |
Why?
|
| Keratins | 1 | 2003 | 175 | 0.050 |
Why?
|
| Combined Modality Therapy | 3 | 2010 | 1204 | 0.050 |
Why?
|
| Smoking | 1 | 2010 | 1460 | 0.050 |
Why?
|
| Drug Resistance, Neoplasm | 2 | 2021 | 749 | 0.050 |
Why?
|
| Estradiol | 1 | 2006 | 486 | 0.050 |
Why?
|
| Prevalence | 4 | 2015 | 2547 | 0.050 |
Why?
|
| Peptide Elongation Factors | 1 | 2022 | 15 | 0.050 |
Why?
|
| Testicular Neoplasms | 1 | 2003 | 102 | 0.050 |
Why?
|
| Aging | 3 | 2010 | 1750 | 0.050 |
Why?
|
| Macrophages | 1 | 2010 | 1460 | 0.050 |
Why?
|
| Adjuvants, Immunologic | 1 | 2023 | 221 | 0.050 |
Why?
|
| Cross-Sectional Studies | 3 | 2020 | 5039 | 0.050 |
Why?
|
| Precancerous Conditions | 1 | 2003 | 161 | 0.050 |
Why?
|
| Promoter Regions, Genetic | 1 | 2006 | 1198 | 0.050 |
Why?
|
| Kidney Transplantation | 1 | 2008 | 602 | 0.050 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 1 | 2010 | 1045 | 0.050 |
Why?
|
| Sarcoma | 1 | 2003 | 176 | 0.050 |
Why?
|
| Lipids | 1 | 2005 | 620 | 0.050 |
Why?
|
| Angiofibroma | 1 | 2001 | 5 | 0.050 |
Why?
|
| Hemangiopericytoma | 1 | 2001 | 5 | 0.050 |
Why?
|
| Phenylthiohydantoin | 1 | 2021 | 44 | 0.050 |
Why?
|
| Histiocytoma, Benign Fibrous | 1 | 2001 | 8 | 0.050 |
Why?
|
| Reactive Oxygen Species | 1 | 2004 | 577 | 0.050 |
Why?
|
| Retreatment | 1 | 2021 | 69 | 0.050 |
Why?
|
| Leukocytes, Mononuclear | 1 | 2024 | 539 | 0.050 |
Why?
|
| Cross-Over Studies | 2 | 2017 | 513 | 0.040 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 1 | 2002 | 235 | 0.040 |
Why?
|
| Microtubule-Associated Proteins | 1 | 2002 | 190 | 0.040 |
Why?
|
| Ephrin-B2 | 1 | 2021 | 50 | 0.040 |
Why?
|
| Growth Substances | 1 | 2001 | 150 | 0.040 |
Why?
|
| Diagnosis, Differential | 3 | 2014 | 1416 | 0.040 |
Why?
|
| Proportional Hazards Models | 2 | 2015 | 1196 | 0.040 |
Why?
|
| Benzamides | 1 | 2021 | 194 | 0.040 |
Why?
|
| Antibodies | 2 | 2002 | 391 | 0.040 |
Why?
|
| 25-Hydroxyvitamin D3 1-alpha-Hydroxylase | 1 | 2020 | 18 | 0.040 |
Why?
|
| Dutasteride | 2 | 2012 | 4 | 0.040 |
Why?
|
| Ovarian Neoplasms | 1 | 2005 | 488 | 0.040 |
Why?
|
| Neutrophils | 2 | 2002 | 1193 | 0.040 |
Why?
|
| Homeodomain Proteins | 1 | 2003 | 490 | 0.040 |
Why?
|
| Soft Tissue Neoplasms | 1 | 2001 | 112 | 0.040 |
Why?
|
| Perineum | 1 | 2019 | 26 | 0.040 |
Why?
|
| Trans-Activators | 1 | 2022 | 381 | 0.040 |
Why?
|
| alpha-Tocopherol | 2 | 2010 | 32 | 0.040 |
Why?
|
| Hypertension, Renovascular | 1 | 1999 | 13 | 0.040 |
Why?
|
| Interleukin-6 | 1 | 2023 | 716 | 0.040 |
Why?
|
| Creatinine | 3 | 2008 | 475 | 0.040 |
Why?
|
| Metabolic Networks and Pathways | 1 | 2020 | 175 | 0.040 |
Why?
|
| Triglycerides | 3 | 2005 | 523 | 0.040 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2004 | 1185 | 0.040 |
Why?
|
| Tissue Array Analysis | 1 | 2018 | 57 | 0.040 |
Why?
|
| Polycystic Kidney, Autosomal Dominant | 1 | 2002 | 223 | 0.040 |
Why?
|
| Polymerase Chain Reaction | 3 | 2009 | 1020 | 0.040 |
Why?
|
| Computer-Aided Design | 1 | 2018 | 41 | 0.040 |
Why?
|
| Flutamide | 1 | 1998 | 5 | 0.040 |
Why?
|
| RNA-Binding Proteins | 1 | 2022 | 388 | 0.040 |
Why?
|
| Automation | 1 | 2018 | 80 | 0.040 |
Why?
|
| Tissue Kallikreins | 1 | 2018 | 2 | 0.040 |
Why?
|
| Dihydrotestosterone | 1 | 1998 | 39 | 0.040 |
Why?
|
| Finite Element Analysis | 1 | 2018 | 72 | 0.040 |
Why?
|
| Ischemia | 1 | 2001 | 395 | 0.040 |
Why?
|
| Neuroimaging | 1 | 2020 | 278 | 0.040 |
Why?
|
| Diagnosis, Computer-Assisted | 1 | 2018 | 87 | 0.040 |
Why?
|
| Life Expectancy | 1 | 1998 | 60 | 0.040 |
Why?
|
| Phosphorylation | 2 | 2013 | 1681 | 0.040 |
Why?
|
| Urological Agents | 1 | 2017 | 3 | 0.030 |
Why?
|
| Lung Neoplasms | 1 | 2010 | 2328 | 0.030 |
Why?
|
| Transcription Factors | 1 | 2005 | 1628 | 0.030 |
Why?
|
| Phantoms, Imaging | 1 | 2018 | 137 | 0.030 |
Why?
|
| Radiotherapy, Adjuvant | 2 | 2009 | 209 | 0.030 |
Why?
|
| Confidence Intervals | 2 | 2008 | 316 | 0.030 |
Why?
|
| Kidney Function Tests | 2 | 2008 | 145 | 0.030 |
Why?
|
| Age Factors | 2 | 2019 | 3103 | 0.030 |
Why?
|
| Matrix Metalloproteinase 10 | 1 | 2016 | 3 | 0.030 |
Why?
|
| rac GTP-Binding Proteins | 1 | 2016 | 32 | 0.030 |
Why?
|
| Laminin | 1 | 2016 | 68 | 0.030 |
Why?
|
| Nitric Oxide | 2 | 2004 | 882 | 0.030 |
Why?
|
| Methylnitrosourea | 1 | 1995 | 7 | 0.030 |
Why?
|
| rhoA GTP-Binding Protein | 1 | 2016 | 90 | 0.030 |
Why?
|
| Cadaver | 1 | 2017 | 325 | 0.030 |
Why?
|
| Rectum | 1 | 2017 | 169 | 0.030 |
Why?
|
| Medical History Taking | 1 | 2016 | 116 | 0.030 |
Why?
|
| Cytokines | 1 | 2004 | 1983 | 0.030 |
Why?
|
| src-Family Kinases | 1 | 2016 | 95 | 0.030 |
Why?
|
| Tosyl Compounds | 1 | 2015 | 16 | 0.030 |
Why?
|
| Down-Regulation | 1 | 1998 | 631 | 0.030 |
Why?
|
| Extracellular Signal-Regulated MAP Kinases | 1 | 2016 | 163 | 0.030 |
Why?
|
| V-Set Domain-Containing T-Cell Activation Inhibitor 1 | 2 | 2005 | 12 | 0.030 |
Why?
|
| Basement Membrane | 2 | 2005 | 30 | 0.030 |
Why?
|
| Oncogenes | 1 | 2016 | 109 | 0.030 |
Why?
|
| Urine | 1 | 2015 | 54 | 0.030 |
Why?
|
| Chromatography, Thin Layer | 1 | 2015 | 22 | 0.030 |
Why?
|
| Chromosomal Instability | 1 | 2015 | 18 | 0.030 |
Why?
|
| Carcinogens | 1 | 1995 | 110 | 0.030 |
Why?
|
| Telomere Homeostasis | 1 | 2015 | 28 | 0.030 |
Why?
|
| Dose-Response Relationship, Drug | 3 | 2007 | 1936 | 0.030 |
Why?
|
| Computational Biology | 1 | 2019 | 598 | 0.030 |
Why?
|
| Anilides | 1 | 2015 | 73 | 0.030 |
Why?
|
| Genetic Association Studies | 1 | 2017 | 361 | 0.030 |
Why?
|
| Prolactinoma | 1 | 2014 | 12 | 0.030 |
Why?
|
| RNA, Messenger | 4 | 2005 | 2675 | 0.030 |
Why?
|
| Liver | 1 | 2023 | 1826 | 0.030 |
Why?
|
| Cystotomy | 1 | 2014 | 4 | 0.030 |
Why?
|
| Surveys and Questionnaires | 3 | 2013 | 5362 | 0.030 |
Why?
|
| Arginine | 1 | 1996 | 258 | 0.030 |
Why?
|
| BRCA1 Protein | 1 | 2014 | 65 | 0.030 |
Why?
|
| Electrophoresis, Polyacrylamide Gel | 1 | 2014 | 323 | 0.030 |
Why?
|
| Referral and Consultation | 1 | 2019 | 727 | 0.030 |
Why?
|
| Chi-Square Distribution | 1 | 2015 | 511 | 0.030 |
Why?
|
| Transfection | 1 | 2016 | 893 | 0.030 |
Why?
|
| Support Vector Machine | 1 | 2014 | 36 | 0.030 |
Why?
|
| Least-Squares Analysis | 1 | 2014 | 72 | 0.030 |
Why?
|
| Extracellular Matrix | 2 | 2010 | 495 | 0.030 |
Why?
|
| Pain Measurement | 1 | 2016 | 487 | 0.030 |
Why?
|
| Phospholipids | 1 | 2015 | 207 | 0.030 |
Why?
|
| Cholesterol | 2 | 2005 | 406 | 0.030 |
Why?
|
| Sodium Tetradecyl Sulfate | 1 | 1993 | 2 | 0.030 |
Why?
|
| Cadherins | 1 | 2015 | 186 | 0.030 |
Why?
|
| Integrin alphaVbeta3 | 1 | 2013 | 19 | 0.030 |
Why?
|
| Two-Hybrid System Techniques | 1 | 2013 | 56 | 0.030 |
Why?
|
| Focal Adhesion Kinase 1 | 1 | 2013 | 29 | 0.030 |
Why?
|
| Receptor Cross-Talk | 1 | 2013 | 21 | 0.030 |
Why?
|
| Sclerotherapy | 1 | 1993 | 19 | 0.030 |
Why?
|
| Electrocoagulation | 1 | 1993 | 38 | 0.030 |
Why?
|
| In Situ Hybridization | 2 | 2005 | 292 | 0.030 |
Why?
|
| Chromosome Aberrations | 2 | 2003 | 148 | 0.030 |
Why?
|
| Cholecystectomy, Laparoscopic | 1 | 1993 | 51 | 0.030 |
Why?
|
| Mass Spectrometry | 1 | 2016 | 659 | 0.030 |
Why?
|
| Cetuximab | 1 | 2013 | 93 | 0.030 |
Why?
|
| Breast Neoplasms | 1 | 2005 | 2132 | 0.030 |
Why?
|
| Human Umbilical Vein Endothelial Cells | 1 | 2013 | 97 | 0.030 |
Why?
|
| Fatty Acids | 2 | 2005 | 415 | 0.020 |
Why?
|
| Databases, Factual | 1 | 2018 | 1269 | 0.020 |
Why?
|
| Kidney Tubules | 2 | 2005 | 114 | 0.020 |
Why?
|
| Up-Regulation | 1 | 2015 | 825 | 0.020 |
Why?
|
| Alleles | 1 | 2015 | 844 | 0.020 |
Why?
|
| Urinary Bladder | 1 | 2014 | 175 | 0.020 |
Why?
|
| Gene Silencing | 1 | 2013 | 185 | 0.020 |
Why?
|
| Interferon-gamma | 1 | 2015 | 759 | 0.020 |
Why?
|
| Blood Chemical Analysis | 1 | 2012 | 94 | 0.020 |
Why?
|
| Receptors, Steroid | 1 | 1992 | 48 | 0.020 |
Why?
|
| Flow Cytometry | 1 | 2015 | 1142 | 0.020 |
Why?
|
| Cardiovascular Diseases | 1 | 2023 | 1999 | 0.020 |
Why?
|
| Caspase 3 | 2 | 2002 | 228 | 0.020 |
Why?
|
| Young Adult | 2 | 2020 | 12312 | 0.020 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2013 | 853 | 0.020 |
Why?
|
| Alkylation | 1 | 2010 | 24 | 0.020 |
Why?
|
| Cyclin A | 1 | 2010 | 17 | 0.020 |
Why?
|
| Gene Expression | 1 | 1996 | 1456 | 0.020 |
Why?
|
| Alzheimer Disease | 1 | 1996 | 516 | 0.020 |
Why?
|
| Cocarcinogenesis | 1 | 2010 | 14 | 0.020 |
Why?
|
| Cytochromes | 1 | 2010 | 10 | 0.020 |
Why?
|
| Amino Acid Sequence | 3 | 2002 | 2040 | 0.020 |
Why?
|
| Algorithms | 1 | 1998 | 1618 | 0.020 |
Why?
|
| Immunoenzyme Techniques | 1 | 2010 | 206 | 0.020 |
Why?
|
| Insulin-Like Growth Factor Binding Protein 3 | 1 | 2010 | 39 | 0.020 |
Why?
|
| Pilot Projects | 1 | 2015 | 1563 | 0.020 |
Why?
|
| Cyclin D1 | 1 | 2010 | 63 | 0.020 |
Why?
|
| Receptors, Retinoic Acid | 1 | 2010 | 51 | 0.020 |
Why?
|
| Weaning | 1 | 2010 | 48 | 0.020 |
Why?
|
| Ki-67 Antigen | 1 | 2010 | 107 | 0.020 |
Why?
|
| Reference Values | 2 | 2005 | 776 | 0.020 |
Why?
|
| Molecular Sequence Data | 3 | 2002 | 2819 | 0.020 |
Why?
|
| Retinoblastoma-Binding Protein 4 | 1 | 2009 | 3 | 0.020 |
Why?
|
| Matrix Metalloproteinases | 1 | 2010 | 89 | 0.020 |
Why?
|
| Selenomethionine | 1 | 2008 | 3 | 0.020 |
Why?
|
| Sirtuin 1 | 1 | 2009 | 30 | 0.020 |
Why?
|
| Multicenter Studies as Topic | 1 | 2010 | 285 | 0.020 |
Why?
|
| Sirtuin 2 | 1 | 2009 | 23 | 0.020 |
Why?
|
| Sirtuins | 1 | 2009 | 37 | 0.020 |
Why?
|
| Antineoplastic Agents, Phytogenic | 1 | 2010 | 185 | 0.020 |
Why?
|
| Species Specificity | 1 | 2010 | 568 | 0.020 |
Why?
|
| Silymarin | 1 | 2010 | 198 | 0.020 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2010 | 421 | 0.020 |
Why?
|
| Ethanol | 1 | 1993 | 584 | 0.020 |
Why?
|
| Adolescent | 4 | 2014 | 20179 | 0.020 |
Why?
|
| Transcriptome | 1 | 2014 | 881 | 0.020 |
Why?
|
| Chromosomal Proteins, Non-Histone | 1 | 2009 | 115 | 0.020 |
Why?
|
| Acetylation | 1 | 2009 | 237 | 0.020 |
Why?
|
| Cell Count | 1 | 2008 | 313 | 0.020 |
Why?
|
| Neurons | 1 | 1996 | 1448 | 0.020 |
Why?
|
| RNA Stability | 1 | 2008 | 100 | 0.020 |
Why?
|
| Insulin-Like Growth Factor I | 1 | 2010 | 307 | 0.020 |
Why?
|
| Molecular Chaperones | 1 | 2009 | 171 | 0.020 |
Why?
|
| Cells, Cultured | 1 | 2015 | 4001 | 0.020 |
Why?
|
| Statistics, Nonparametric | 1 | 2008 | 418 | 0.020 |
Why?
|
| HeLa Cells | 1 | 2009 | 603 | 0.020 |
Why?
|
| Histone Deacetylases | 1 | 2009 | 210 | 0.020 |
Why?
|
| Drosophila Proteins | 1 | 2009 | 187 | 0.020 |
Why?
|
| Preventive Medicine | 1 | 2007 | 41 | 0.020 |
Why?
|
| Doxorubicin | 1 | 2008 | 322 | 0.020 |
Why?
|
| Cell Differentiation | 1 | 2014 | 1900 | 0.020 |
Why?
|
| Protein Binding | 1 | 2013 | 2103 | 0.020 |
Why?
|
| Incidental Findings | 1 | 2007 | 79 | 0.020 |
Why?
|
| Enzyme Induction | 2 | 1996 | 89 | 0.020 |
Why?
|
| Probability | 1 | 2007 | 305 | 0.020 |
Why?
|
| Neoplasms | 2 | 2013 | 2464 | 0.020 |
Why?
|
| Radiotherapy Dosage | 1 | 2006 | 249 | 0.020 |
Why?
|
| Periodic Acid-Schiff Reaction | 1 | 2005 | 3 | 0.020 |
Why?
|
| ATP Citrate (pro-S)-Lyase | 1 | 2005 | 3 | 0.020 |
Why?
|
| Biliary Tract | 1 | 2005 | 15 | 0.020 |
Why?
|
| Adenocarcinoma, Clear Cell | 1 | 2005 | 14 | 0.020 |
Why?
|
| Area Under Curve | 1 | 2006 | 279 | 0.020 |
Why?
|
| Disease-Free Survival | 1 | 2007 | 647 | 0.020 |
Why?
|
| Preoperative Care | 1 | 2008 | 338 | 0.020 |
Why?
|
| Densitometry | 1 | 2005 | 33 | 0.020 |
Why?
|
| Congresses as Topic | 1 | 2007 | 212 | 0.020 |
Why?
|
| Azo Compounds | 1 | 2005 | 26 | 0.020 |
Why?
|
| Collagen Type IV | 1 | 2005 | 22 | 0.020 |
Why?
|
| Linear Models | 1 | 2008 | 813 | 0.020 |
Why?
|
| Carcinoma, Endometrioid | 1 | 2005 | 47 | 0.020 |
Why?
|
| Drug Administration Schedule | 1 | 2007 | 751 | 0.020 |
Why?
|
| Forecasting | 1 | 2007 | 358 | 0.020 |
Why?
|
| Graft Survival | 1 | 2008 | 503 | 0.020 |
Why?
|
| Cell Cycle Proteins | 1 | 2009 | 577 | 0.010 |
Why?
|
| Podocytes | 1 | 2005 | 51 | 0.010 |
Why?
|
| Skin Diseases | 1 | 2007 | 141 | 0.010 |
Why?
|
| Administration, Oral | 1 | 2007 | 754 | 0.010 |
Why?
|
| Plasminogen Activator Inhibitor 1 | 1 | 2005 | 83 | 0.010 |
Why?
|
| Glycosylation | 1 | 2005 | 146 | 0.010 |
Why?
|
| Cystadenocarcinoma, Serous | 1 | 2005 | 68 | 0.010 |
Why?
|
| Fibronectins | 1 | 2005 | 120 | 0.010 |
Why?
|
| Adenocarcinoma, Mucinous | 1 | 2005 | 75 | 0.010 |
Why?
|
| Rats, Inbred F344 | 1 | 2005 | 251 | 0.010 |
Why?
|
| Anxiety | 1 | 2012 | 954 | 0.010 |
Why?
|
| Renal Circulation | 1 | 2004 | 57 | 0.010 |
Why?
|
| Complement C3d | 1 | 2005 | 64 | 0.010 |
Why?
|
| Rats, Sprague-Dawley | 1 | 2010 | 2239 | 0.010 |
Why?
|
| Perfusion | 1 | 2005 | 188 | 0.010 |
Why?
|
| Brain | 1 | 1996 | 2620 | 0.010 |
Why?
|
| Oxidative Stress | 1 | 2010 | 1176 | 0.010 |
Why?
|
| Nitric Oxide Synthase Type II | 1 | 2004 | 167 | 0.010 |
Why?
|
| Mice, Knockout | 2 | 2004 | 2755 | 0.010 |
Why?
|
| Infant | 3 | 2005 | 8914 | 0.010 |
Why?
|
| Breast | 1 | 2005 | 152 | 0.010 |
Why?
|
| Spectral Karyotyping | 1 | 2003 | 5 | 0.010 |
Why?
|
| Leptin | 1 | 2005 | 218 | 0.010 |
Why?
|
| Nitric Oxide Synthase Type III | 1 | 2004 | 197 | 0.010 |
Why?
|
| Sodium | 1 | 2004 | 205 | 0.010 |
Why?
|
| Hypoxia | 1 | 2010 | 1036 | 0.010 |
Why?
|
| Mutation | 1 | 2014 | 3689 | 0.010 |
Why?
|
| Vena Cava, Inferior | 1 | 2003 | 68 | 0.010 |
Why?
|
| Renal Dialysis | 1 | 2007 | 417 | 0.010 |
Why?
|
| Heart Atria | 1 | 2003 | 127 | 0.010 |
Why?
|
| Amino Acid Chloromethyl Ketones | 1 | 2002 | 24 | 0.010 |
Why?
|
| Cysteine Proteinase Inhibitors | 1 | 2002 | 48 | 0.010 |
Why?
|
| Colorado | 1 | 2012 | 4375 | 0.010 |
Why?
|
| Caspase Inhibitors | 1 | 2002 | 76 | 0.010 |
Why?
|
| Inhibitor of Apoptosis Proteins | 1 | 2002 | 45 | 0.010 |
Why?
|
| Cell Nucleus | 1 | 2005 | 578 | 0.010 |
Why?
|
| Morbidity | 1 | 2003 | 301 | 0.010 |
Why?
|
| bcl-X Protein | 1 | 2002 | 41 | 0.010 |
Why?
|
| Lymphocyte Depletion | 1 | 2002 | 129 | 0.010 |
Why?
|
| Antiviral Agents | 1 | 2008 | 703 | 0.010 |
Why?
|
| In Situ Nick-End Labeling | 1 | 2002 | 120 | 0.010 |
Why?
|
| Genomics | 1 | 2007 | 715 | 0.010 |
Why?
|
| Poly(ADP-ribose) Polymerases | 1 | 2002 | 87 | 0.010 |
Why?
|
| Kidney Tubules, Proximal | 1 | 2002 | 125 | 0.010 |
Why?
|
| Mucous Membrane | 1 | 2002 | 120 | 0.010 |
Why?
|
| Quinolines | 1 | 2002 | 153 | 0.010 |
Why?
|
| Neutralization Tests | 1 | 2001 | 73 | 0.010 |
Why?
|
| Lipopolysaccharides | 1 | 2004 | 856 | 0.010 |
Why?
|
| Analysis of Variance | 1 | 2003 | 1269 | 0.010 |
Why?
|
| Drug Therapy, Combination | 1 | 2003 | 1009 | 0.010 |
Why?
|
| Mice, Mutant Strains | 1 | 2001 | 292 | 0.010 |
Why?
|
| Peroxidase | 1 | 2001 | 169 | 0.010 |
Why?
|
| Mice, Transgenic | 1 | 2006 | 2071 | 0.010 |
Why?
|
| Mass Screening | 1 | 2008 | 1146 | 0.010 |
Why?
|
| Echocardiography | 1 | 2003 | 623 | 0.010 |
Why?
|
| Proteomics | 1 | 2007 | 1009 | 0.010 |
Why?
|
| Inflammation Mediators | 1 | 2002 | 495 | 0.010 |
Why?
|
| Epithelial Cells | 1 | 2005 | 1032 | 0.010 |
Why?
|
| Child, Preschool | 2 | 2005 | 10384 | 0.010 |
Why?
|
| RNA | 1 | 2005 | 880 | 0.010 |
Why?
|
| False Negative Reactions | 1 | 1998 | 51 | 0.010 |
Why?
|
| Diet | 1 | 2006 | 1199 | 0.010 |
Why?
|
| Models, Biological | 1 | 2005 | 1691 | 0.010 |
Why?
|
| Blood Pressure | 1 | 2004 | 1728 | 0.010 |
Why?
|
| Lung | 1 | 2010 | 3743 | 0.010 |
Why?
|
| Pregnancy | 1 | 2010 | 6357 | 0.010 |
Why?
|
| omega-N-Methylarginine | 1 | 1996 | 26 | 0.010 |
Why?
|
| Antibody Specificity | 1 | 1996 | 182 | 0.010 |
Why?
|
| NG-Nitroarginine Methyl Ester | 1 | 1996 | 46 | 0.010 |
Why?
|
| Blotting, Northern | 1 | 1996 | 198 | 0.010 |
Why?
|
| Immunoblotting | 1 | 1996 | 300 | 0.010 |
Why?
|
| Nitrites | 1 | 1996 | 81 | 0.010 |
Why?
|
| Nitrates | 1 | 1996 | 87 | 0.010 |
Why?
|
| Cardiomyopathy, Dilated | 1 | 1999 | 377 | 0.010 |
Why?
|
| Blood Glucose | 1 | 2005 | 2093 | 0.010 |
Why?
|
| Endothelium, Vascular | 1 | 2001 | 847 | 0.010 |
Why?
|
| Child | 2 | 2005 | 20655 | 0.010 |
Why?
|
| Metribolone | 1 | 1992 | 5 | 0.010 |
Why?
|
| Centrifugation, Density Gradient | 1 | 1992 | 39 | 0.010 |
Why?
|
| Peptide Fragments | 1 | 1996 | 684 | 0.010 |
Why?
|
| Chromatography, Affinity | 1 | 1992 | 83 | 0.010 |
Why?
|
| Binding, Competitive | 1 | 1992 | 199 | 0.010 |
Why?
|
| Cytosol | 1 | 1992 | 214 | 0.010 |
Why?
|
| Myocardium | 1 | 1996 | 965 | 0.010 |
Why?
|
| Infant, Newborn | 1 | 2001 | 5687 | 0.010 |
Why?
|
| Tomography, X-Ray Computed | 1 | 1999 | 2523 | 0.000 |
Why?
|
| Kinetics | 1 | 1992 | 1615 | 0.000 |
Why?
|